Leukotriene receptor antagonists for chronic urticaria: a systematic review

Allergy, Asthma & Clinical Immunology

Nipun Lakshitha de Silva³  Hasitha Damayanthi²  Anoja Chamarie Rajapakse¹  Chaturaka Rodrigo³  Senaka Rajapakse³ 

[1] Department of Geriatrics, Kings Mill Hospital, Sherwood Forest NHS Foundation Trust, Sutton-in-Ashfield, Nottinghamshire, UK

[2] Department of Pharmacology, Faculty of Medicine, Colombo, Sri Lanka

[3] Department of Clinical Medicine, Faculty of Medicine, University of Colombo, 25 Kynsey Road, Colombo 08, Sri Lanka

关键词: Antihistamines;    Zafirlukast;    Montelukast;    Leukotreine;    Leukotreine receptor antagonists;    Chronic urticaria;   

Others  :  791790
DOI  :  10.1186/1710-1492-10-24

 received in 2014-02-01, accepted in 2014-04-13,  发布年份 2014

【 摘 要 】

A significant proportion of patients with chronic urticaria respond inadequately to first line treatment with antihistamines. Leukotreine receptor antagonists (LTRA) are also used for chronic urticaria, although firm recommendations on their use are lacking. We performed a systematic review of randomised trials to determine the role of LTRA in treatment of chronic urticaria. A search of PUBMED, EMBASE, SCOPUS, LILACS, the Cochrane Central Register of Controlled Trials, and the Web of Science for relevant randomized control trials or cross over studies yielded 10 eligible studies. The heterogeneity of trials were high, preventing valid meta-analysis of data. Most trials indicated that LTRA are not superior to placebo or antihistamine therapy, while combination therapy of LTRA and antihistamines appear to be more efficacious compared to antihistamine alone. The side effect profile and tolerability of this group of drugs is acceptable. The use of LTRA as monotherapy cannot be recommended. LTRA are effective add-on therapy to anti-histamines, and their use in patients responding poorly to antihistamines is justifiable. Further well designed randomized controlled trials with clear and standardized outcome measures are needed to determine the role of LTRA in chronic urticaria.

【 授权许可】

   
2014 de Silva et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Kanani A, Schellenberg R, Warrington R: Urticaria and angioedema. Allergy Asthma Clin Immunol 2011, 7(1):S9. BioMed Central Full Text
• [2]Greaves M: Chronic urticaria. J Allergy Clin Immunol 2000, 105(4):664-672.
• [3]Kaplan AP: Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol 2004, 114(3):465-474. quiz 475
• [4]Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Gimenez-Arnau A, Grattan CE, Kapp A, Merk HF, Rogala B, Saini S, Sanchez-Borges M, Schmid-Grendelmeier P, Schunemann H, Staubach P, Vena GA, Wedi B, Maurer M: EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy 2009, 64(10):1417-1426.
• [5]Altman K, Chang C: Pathogenic intracellular and autoimmune mechanisms in Urticaria and Angioedema. Clin Rev Allergy Immunol 2012, 1-16.
• [6]Greaves M: Management of urticaria. Hosp Med 2000, 61(7):463-469.
• [7]Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Gimenez-Arnau AM, Grattan CE, Kapp A, Maurer M, Merk HF, Rogala B, Saini S, Sanchez-Borges M, Schmid-Grendelmeier P, Schunemann H, Staubach P, Vena GA, Wedi B: EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy 2009, 64(10):1427-1443.
• [8]Nam YH, Kim JH, Jin HJ, Hwang EK, Shin YS, Ye YM, Park HS: Effects of omalizumab treatment in patients with refractory chronic urticaria. Allergy, Asthma and Immunology Research 2012, 4(6):357-361.
• [9]Riccioni G, Bucciarelli T, Mancini B, Di Ilio C, D’Orazio N: Antileukotriene drugs: clinical application, effectiveness and safety. Curr Med Chem 2007, 14(18):1966-1977.
• [10]McBayne TO, Siddall OM: Montelukast treatment of urticaria. Ann Pharmacother 2006, 40(5):939-942.
• [11]Di Lorenzo G, D’Alcamo A, Rizzo M, Leto-Barone MS, Lo Bianco C, Ditta V, Politi D, Castello F, Pepe I, Rini G: Leukotriene receptor antagonists in monotherapy or in combination with antihistamines in the treatment of chronic urticaria: a systematic review. Journal of Asthma and Allergy 2009, 2:9-16.
• [12]Agcaoili ML, Sumpaico MW, Aleta LA, Recto MP, Abong JM: Montelukast in the treatment of chronic Urticaria: a randomized double blind, placebocontrolled study. Ann Allergy Asthma Immunol 2011, 107(5):Supplement 1.
• [13]Di Lorenzo G, Pacor ML, Mansueto P, Esposito Pellitteri M, Lo Bianco C, Ditta V, Martinelli N, Rini GB: Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria. J Allergy Clin Immunol 2004, 114(3):619-625.
• [14]Nettis E, Colanardi MC, Paradiso MT, Ferrannini A: Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study. Clin Exp Allergy 2004, 34(9):1401-1407.
• [15]Kosnik M, Subic T: Add-on montelukast in antihistamine-resistant chronic idiopathic urticaria. Respir Med 2011, 105(SUPPL. 1):S84-S88.
• [16]Erbagci Z: The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: a single-blind, placebo-controlled, crossover clinical study. J Allergy Clin Immunol 2002, 110(3):484-488.
• [17]Reimers A, Pichler C, Helbling A, Pichler WJ, Yawalkar N: Zafirlukast has no beneficial effects in the treatment of chronic urticaria. Clin Exp Allergy 2002, 32(12):1763-1768.
• [18]Nettis E, Pannofino A, Cavallo E, Ferrannini A, Tursi A: Efficacy of montelukast, in combination with loratadine, in the treatment of delayed pressure urticaria. J Allergy Clin Immunol 2003, 112(1):212-213.
• [19]Pacor ML, Di G, Corrocher R: Efficacy of leukotriene receptor antagonist in chronic urticaria: a double-blind, placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or acetylsalicylic acid. Clin Exp Allergy 2001, 31(10):1607-1614.
• [20]Bagenstose SE, Levin L, Bernstein JA: The addition of zafirlukast to cetirizine improves the treatment of chronic urticaria in patients with positive autologous serum skin test results. J Allergy Clin Immunol 2004, 113(1):134-140.
• [21]Wan KS: Efficacy of leukotriene receptor antagonist with an anti-H1 receptor antagonist for treatment of chronic idiopathic urticaria. J Dermatol Treat 2009, 20(4):194-197.
• [22]Godse KV: Oral montelukast monotherapy is ineffective in chronic idiopathic urticaria: a comparison with oral cetirizine. Indian J Dermatol Venereol Leprol 2006, 72(4):312-314.
• [23]Nettis E, Dambra P, D’Oronzio L, Loria MP, Ferrannini A, Tursi A: Comparison of montelukast and fexofenadine for chronic idiopathic urticaria. Arch Dermatol 2001, 137(1):99-100.
• [24]Leukotriene receptor antagonists. British National Formulary. London: BMJ Group and the Royal Pharmaceutical Society of Great Britain; 2013:198-199.